Cadherin-11 EC1 domain antagonists for treating inflammatory joint disorders
AssigneeAdheron Therapeutics, Inc.
InventorJames G. McArthur
Life of this patent
Estimating the term…
Abstract
The present invention relates to Cadherin-11 antagonists and compositions comprising Cadherin-11 antagonists. The invention also relates to methods for treating inflammatory joint disorders, such as rheumaotid arthritis, in a mammalian subject by administering a therapeutically effective amount of a Cadherin-11 antagonist.
Claims17
An isolated antibody that specifically binds an EC1 domain of a mammalian Cadherin-11 protein, wherein the antibody binds an epitope comprising SEQ ID NO:11, or an epitope that is present in SEQ ID NO:12, in the EC1 domain of the mammalian Cadherin-11 protein.
A pharmaceutical composition comprising an antibody that specifically binds an EC1 domain of a mammalian Cadherin-11 protein, wherein the antibody binds an epitope comprising SEQ ID NO:11, or an epitope that is present in SEQ ID NO:12, in the EC1 domain of the mammalian Cadherin-11 protein.
Dependencies are inferred from the claim text.